Preventing Alzheimer’s Disease

  title={Preventing Alzheimer’s Disease},
  author={Mary Sano and Hillel T. Grossman and Kathleen M. Van Dyk},
  journal={CNS Drugs},
Alzheimer’s disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments.In the past two decades, clinical trials have led to the approval of symptomatic treatments for… 

Taming Alzheimer’s disease: New perspectives, newer horizons

It is now possible to detect preclinical AD and also monitor its progression in asymptomatic people and to validate and standardize these biomarkers and select the most reliable, repeatable, easily available, cost-effective and complementary options is the challenge ahead.

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease

Re-analysis of AD patient-level data from failed clinical trials suggested by trend that use of simvastatin may slow the progression of cognitive decline, and to a greater extent in ApoE4 homozygotes, and results indicate that the use of statins may benefit all AD patients with potentially greater therapeutic efficacy in those homozygous for ApOE4.

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic

Several findings indicate that the activation of both CB1 and CB2 receptors by natural or synthetic agonists, at non-psychoactive doses, have beneficial effects in Alzheimer experimental models by reducing the harmful β-amyloid peptide action and tau phosphorylation, as well as by promoting the brain's intrinsic repair mechanisms.

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Targets of developing drugs in AD pathophysiology are summarized, including cerebrospinal fluid (CSF) Aβ1-42, total tau and p-tau181 levels, and imagining biomarkers, which are now being actively integrated into the designs of AD clinical trials.

Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease.

Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease

This paper outlines and evaluates the current landscape of preclinical and clinical studies focusing on modulating Aβ pathophysiology and suggests the most promising approach seems to be the prevention of early Aβ oligomerization.

The therapeutics of Alzheimer's disease: Where we stand and where we are heading

  • D. Selkoe
  • Biology, Psychology
    Annals of neurology
  • 2013
The pace of recent developments augurs well for 1 or more experimental agents being shown to slow cognitive decline without major side effects, however, research funding from all sources will need to increase dramatically and soon to stave off the approaching tsunami of AD.

Alzheimer's disease immunization strategies : a review of current research

The immunizations entering final clinical trial phases appear to delay the onset or improve symptom control in Alzheimer’s disease, but do not seem to provide a cure at this time.

Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

Critical issues in “immunotherapy” and “anti-insulin resistance” therapy in relation to therapeutic strategies against neurodegenerative disease are focused on, and how they might merge mechanistically at the point of suppression of protein aggregation is focused on.

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease

The contributions of impaired insulin and IGF signaling to AD-associated neuronal loss, synaptic disconnection, tau hyperphosphorylation, amyloid-beta accumulation, and impaired energy metabolism are reviewed and current therapeutic strategies are discussed.



Disease-modifying therapies for Alzheimer disease

Enrichment strategies for clinical trials with MCI include use of biomarkers such as amyloid imaging, MRI with demonstration of medial temporal lobe atrophy, bilateral parietal hypometabolism on PET, and reduced amyloids beta peptide and increased tau protein in CSF.

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial.

Alzheimer’s disease: the impact of age-related changes in reproductive hormones

Results of these animal and tissue culture models suggest that the loss of both estrogens and progestins at the menopause makes the brain more vulnerable to acute insults and chronic neurodegenerative diseases.

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease

LLAs may slow cognitive decline in Alzheimer’s disease and have a neuroprotective effect and should be confirmed by placebo controlled randomised trials in patients with Alzheimer's disease and no dyslipaemia.

Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study

The failure of selective cyclo-oxygenase–2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo’s enzyme does not play a significant role in the pathogenesis of the disorder.

Neuroinflammatory perspectives on the two faces of Alzheimer’s disease

The evidence that inflammation related events could be a critical etiological factor in certain forms of the sporadic AD is reviewed, suggesting that inflammatory mechanisms are most likely involved in the early steps of the pathological cascade.

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.

Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease

Iebenone failed to slow cognitive decline in AD that was of sufficient magnitude to be clinically significant.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.